A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Morschhauser, F; Seymour, J F; Kluin-Nelemans, H C; Grigg, A; Wolf, M; Pfreundschuh, M; Tilly, H; Raemaekers, J; van 't Veer, M B; Milpied, N; Cartron, G; Pezzutto, A; Spencer, A; Reyes, F; Dreyling, M

Morschhauser, F; Seymour, J F; Kluin-Nelemans, H C; Grigg, A; Wolf, M; Pfreundschuh, M; Tilly, H; Raemaekers, J; van 't Veer, M B; Milpied, N; Cartron, G; Pezzutto, A; Spencer, A; Reyes, F; Dreyling, M.

Affiliation

Morschhauser F; Hematology, Hopital C. Huriez Centre Hospitalier Universitaire, Lille, France. f-morschhauser@chru-lille.fr

Ann Oncol ; 19(2): 247-53, 2008 Feb.

Article in En | MEDLINE | ID: mdl-17906297

Subject(s)

Indoles/administration & dosage; Lymphoma, Mantle-Cell/drug therapy; Lymphoma, Mantle-Cell/mortality; Protein Kinase C/antagonists & inhibitors; Administration, Oral; Aged; Aged, 80 and over; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles/adverse effects; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell/pathology; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Protein Kinase C/administration & dosage; Protein Kinase C beta; Protein Kinase Inhibitors/administration & dosage; Recurrence; Survival Analysis; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 3_ND / 4_TD / 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Protein Kinase C / Lymphoma, Mantle-Cell / Indoles Type of study: Prognostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Year: 2008 Document type: Article

Search on Google

XML

PubMed Links